OncoMed Pharma (OMED) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
May 8, 2017 6:50 AM EDTQ1 Cash Balance of $156.9M Cash Through Q3 2019
Phase 2 Demcizumab DENALI Non-Small Cell Lung Cancer Trial Did Not Meet Endpoints
Focused on Immuno-Oncology Pipeline and Celgene Collaboration Programs
Management to Host Conference Call/Webcast this Morning at 8:30 a.m. ET / 5:30 a.m. PT
REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced first quarter financial results. As of March 31, 2017, cash, and short-term... More
